NCT06116110Recruiting
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 30 Oct 2023
- Start date
- 15 May 2024
- Primary completion date
- 1 Dec 2041
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06116110
What you commit to
- Study type: Observational
- Planned participants: 150
- From 15 May 2024 to the primary completion date, 1 Dec 2041
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up.
- Provided written informed consent to participate in this study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center Coordinator of this site? Confirm its status | Baltimore | United States | Not yet recruiting |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Robert H Lurie Cancer Center Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| UT Southwestern Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Duke University Medical Center - Division of Hematologic Malignancies Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
| Banner MD Anderson Cancer Center Coordinator of this site? Confirm its status | Gilbert | United States | Recruiting |
| Froedtert Hospital and the Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
| Yale University Coordinator of this site? Confirm its status | New Haven | United States | Recruiting |
| Oregon Health and Science University Knight Cancer Institute Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| Stanford University Coordinator of this site? Confirm its status | Stanford | United States | Recruiting |
| University of Kansas Cancer Center Coordinator of this site? Confirm its status | Westwood | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.